R H Haubrich

Summary

Affiliation: University of California
Country: USA

Publications

  1. ncbi Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data
    Kit N Simpson
    Medical University of South Carolina, SC, USA
    Cost Eff Resour Alloc 9:5. 2011
  2. ncbi A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy
    R H Haubrich
    Department of Medicine and University of California San Diego UCSD Treatment Center Data and Biostatistical Unit, UCSD, San Diego, CA 92103, USA
    Clin Infect Dis 33:1060-8. 2001
  3. ncbi Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment
    Richard H Haubrich
    University of California San Diego, San Diego, California 92103, USA
    AIDS 23:1109-18. 2009
  4. ncbi Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359
    Richard H Haubrich
    University of California San Diego, San Diego, California 92103, USA
    HIV Clin Trials 8:63-7. 2007
  5. ncbi Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients
    Richard Haubrich
    University of California San Diego, San Diego, CA 92103, USA
    AIDS 21:F11-8. 2007
  6. ncbi A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575
    Richard H Haubrich
    University of California, San Diego, California, USA
    AIDS 19:295-302. 2005
  7. ncbi Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
    Richard H Haubrich
    Antiviral Research Center, University of California San Diego, San Diego, California 92103, USA
    AIDS 25:2269-78. 2011
  8. ncbi The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis
    Richard H Haubrich
    University of California at San Diego, San Diego, California, USA
    AIDS 16:F33-40. 2002
  9. ncbi A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Brookie M Best
    University of California, San Diego, San Diego, CA 92013, USA
    J Acquir Immune Defic Syndr 46:433-42. 2007
  10. ncbi The use of pooled viral load testing to identify antiretroviral treatment failure
    Davey M Smith
    University of California San Diego, La Jolla, CA 92093 0679, USA
    AIDS 23:2151-8. 2009

Research Grants

  1. Improving Antiretroviral Management for HIV
    Richard Haubrich; Fiscal Year: 2007

Detail Information

Publications15

  1. ncbi Economic modeling of the combined effects of HIV-disease, cholesterol and lipoatrophy based on ACTG 5142 trial data
    Kit N Simpson
    Medical University of South Carolina, SC, USA
    Cost Eff Resour Alloc 9:5. 2011
    ..abstract:..
  2. ncbi A randomized study of the utility of human immunodeficiency virus RNA measurement for the management of antiretroviral therapy
    R H Haubrich
    Department of Medicine and University of California San Diego UCSD Treatment Center Data and Biostatistical Unit, UCSD, San Diego, CA 92103, USA
    Clin Infect Dis 33:1060-8. 2001
    ..0002). A trend (P=.1) toward improved survival was seen in the frequent group. Given this improved virological response, more frequent HIV RNA measurement than is recommended in published guidelines (every 3-4 months) may be appropriate...
  3. ncbi Metabolic outcomes in a randomized trial of nucleoside, nonnucleoside and protease inhibitor-sparing regimens for initial HIV treatment
    Richard H Haubrich
    University of California San Diego, San Diego, California 92103, USA
    AIDS 23:1109-18. 2009
    ..The metabolic effects of initial therapy for HIV-1 infection are important determinants of regimen selection...
  4. ncbi Non-nucleoside phenotypic hypersusceptibility cut-point determination from ACTG 359
    Richard H Haubrich
    University of California San Diego, San Diego, California 92103, USA
    HIV Clin Trials 8:63-7. 2007
    ....
  5. ncbi Week 24 efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients
    Richard Haubrich
    University of California San Diego, San Diego, CA 92103, USA
    AIDS 21:F11-8. 2007
    ..Agents for the treatment of HIV-1-infected patients with resistance to current antiretroviral (ART) drugs are needed...
  6. ncbi A randomized, prospective study of phenotype susceptibility testing versus standard of care to manage antiretroviral therapy: CCTG 575
    Richard H Haubrich
    University of California, San Diego, California, USA
    AIDS 19:295-302. 2005
    ..To assess phenotype susceptibility testing (PHENO) with standard of care (SOC) to improve antiretroviral therapy...
  7. ncbi Initial viral decay to assess the relative antiretroviral potency of protease inhibitor-sparing, nonnucleoside reverse transcriptase inhibitor-sparing, and nucleoside reverse transcriptase inhibitor-sparing regimens for first-line therapy of HIV infection
    Richard H Haubrich
    Antiviral Research Center, University of California San Diego, San Diego, California 92103, USA
    AIDS 25:2269-78. 2011
    ..To evaluate the effects of sex and initial antiretroviral regimen on decay of HIV-RNA and virologic outcome...
  8. ncbi The clinical relevance of non-nucleoside reverse transcriptase inhibitor hypersusceptibility: a prospective cohort analysis
    Richard H Haubrich
    University of California at San Diego, San Diego, California, USA
    AIDS 16:F33-40. 2002
    ..1). CONCLUSION: NNRTI hypersusceptibility occurred in more than 20% of nucleoside-experienced patients and was associated with greater reduction of HIV RNA and increase in CD4 cells...
  9. ncbi A randomized controlled trial of therapeutic drug monitoring in treatment-naive and -experienced HIV-1-infected patients
    Brookie M Best
    University of California, San Diego, San Diego, CA 92013, USA
    J Acquir Immune Defic Syndr 46:433-42. 2007
    ..To improve the utility of therapeutic drug monitoring (TDM) by defining the proportion of patients with and predictors of above or below target protease inhibitor (PI) or nonnucleoside reverse transcriptase inhibitor (NNRTI) concentrations...
  10. ncbi The use of pooled viral load testing to identify antiretroviral treatment failure
    Davey M Smith
    University of California San Diego, La Jolla, CA 92093 0679, USA
    AIDS 23:2151-8. 2009
    ....
  11. ncbi The correlation between plasma concentrations of protease inhibitors, medication adherence and virological outcome in HIV-infected patients
    Julie M Yasuda
    San Diego State University, San Diego, Calif, USA
    Antivir Ther 9:753-61. 2004
    ..CONCLUSIONS: Repeated, random PI concentration values are independently predictive of virological response and may add to self-report of adherence in understanding the response to ART...
  12. ncbi Resistance and replication capacity assays: clinical utility and interpretation
    Richard H Haubrich
    Division of Infectious Diseases, University of California San Diego, USA
    Top HIV Med 12:52-6. 2004
    ..This article summarizes a presentation given by Richard H. Haubrich, MD, at the International AIDS Society-USA Sacramento course in November 2003...
  13. ncbi Defining treatment failure in resource-rich settings
    Jeannette L Aldous
    University of California San Diego, Department of Medicine, Division of Infectious Diseases, Antiretroviral Research Center AVRC, San Diego, California 92103, USA
    Curr Opin HIV AIDS 4:459-66. 2009
    ..To define treatment failure in resource-rich settings; summarizing current guidelines, assays, the significance of detectable viremia, and definitions of treatment failure in clinical and research settings...
  14. ncbi Cognitive-behavioral intervention to enhance adherence to antiretroviral therapy: a randomized controlled trial (CCTG 578)
    Glenn J Wagner
    RAND Corporation, 1776 Main Street, Santa Monica, CA 90407, USA
    AIDS 20:1295-302. 2006
    ..We conducted a randomized, multi-site, controlled trial of a cognitive-behavioral adherence intervention for patients initiating or changing an antiretroviral (ART) regimen...
  15. ncbi Nucleoside and nucleotide analogue reverse transcriptase inhibitors: a clinical review of antiretroviral resistance
    Joel E Gallant
    The Johns Hopkins University, Baltimore, MD, USA
    Antivir Ther 8:489-506. 2003
    ..This review summarizes research advances that further the understanding of nucleoside and nucleotide analogue resistance mutations, and their interplay...

Research Grants4

  1. Improving Antiretroviral Management for HIV
    Richard Haubrich; Fiscal Year: 2007
    ..Aim 2B: To define the impact of genetic differences (defined by allelic variants of single nucleoside polymorphisms) on exposure and response to lopinavir, the antiretroviral agent. ..